组蛋白去乙酰化酶抑制剂抗感染性休克治疗动物实验的研究进展

Research progress of histone deacetylase inhibitors in the theraphy of anti-sepsis shock in animal experiments

组蛋白去乙酰化酶抑制剂作为抗肿瘤、神经退行性病变、免疫系统疾病等治疗药物已成功应用于临床。值得注意的是，其凭借促生存和抗炎特性成为新型的抗感染休克药物，能在分子水平上逆转由于感染性休克及其后续液体复苏造成的基因表达变化，重要的是对血流动力学产生影响轻微，最终阻断病变向全身炎症反应综合征和多器官衰竭综合征的发展，从而为争取治疗“黄金时问”打下了良好基础；另一方面，随着“二次打击”理论的发展，它也将架起失血性休克与感染性休克之间的桥梁，拓展了在休克领域的认识。因此，组蛋白去乙酰化酶抑制剂是对传统抗感染性休克治疗的延伸和挑战。

It has demonstrated histone deacetylase inhibitor to be protective in preclinical and early clinical studies for the therapy of cancer, central nervous system degenerative diseases and immune system diseases. Strikingly, Recent studies have shown that it has emerged as a potent prosurvival and anti-inflammatory drug, offering new lines of therapeutic intervention for sepsis shock, and can reverse the changes of genes expression at the molecular level, caused by sepsis shock and its follow-up of fluid resuscitation. What＇ s more, it has slight impact on hemodynamics, ultimately alleviates lesions to systemic inflammatory response syndrome and multiple organ failure syndrome and simultaneously lays a good foundation to win the golden time for treatment. On the other hand, with the development of ＂second hit＂ theory, it will also set up a bridge between hemorrhagic shock and septic shock, resulting in expansioning the breadth and depth of understanding of shock. In brief, histone deacetylase inhibitors are the extension and challenges of the traditional therapy of anti-sepsis shock.